Depression is a frequent finding in patients with neurological disorders. These depressions, however, have similar phenomenology, duration, biological markers, and response to treatment as depressions in patients with no known brain injuries (i.e., functional depression). In the present article, we review evidence that suggests the dementia of depression exists among severely depressed patients with cerebrovascular lesions or Parkinson's disease (PD). We conclude that: a) in patients with either stroke lesions or PD, depression is significantly associated with cognitive deficits; b) this association is only true for patients with major depression (i.e., it is not present in patients with minor depression); and c) patients with poststroke depression and patients with PD and depression have a severity and profile of cognitive deficits similar to those found in patients with primary major depression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00005053-199110000-00002 | DOI Listing |
Front Pediatr
January 2025
Department of Medical Psychology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Narcolepsy is a sleep-wake disorder with an onset commonly seen in individuals aged 10-30 years. Due to various reasons, the diagnosis of narcolepsy often experiences a delay of at least ten years. Diagnosing narcolepsy in children is particularly challenging due to atypical symptoms, leading to frequent misdiagnosis or missed diagnoses.
View Article and Find Full Text PDFInt Med Case Rep J
January 2025
Department of Neurology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, People's Republic of China.
Background: Coexistence of autoimmune encephalitis (AE) with multiple autoantibodies is of particular concern because overlying antibodies may cause variation of clinical manifestations. Coexistence of anti-glutamic acid decarboxylase (GAD) and anti-Gamma-aminobutyric acid-α-receptor (GABAAR) antibodies in AE was rare.
Case Presentation: A 44-year-old female patient presented to our hospital due to cognitive decline for 4 years, seizures, slowed speech and depression for 2 months.
Cureus
December 2024
Ernest Mario School of Pharmacy, Rutgers University, Piscataway, USA.
Objective: Patients with major depressive disorder (MDD) often face poor health outcomes. Additionally, patients with multiple hospitalizations tend to have worse predicted disease prognosis. Antidepressant medications remain a first-line treatment option for MDD, but data evaluating the effects of different antidepressants on psychiatric readmission rates is lacking.
View Article and Find Full Text PDFJ Pain Res
January 2025
Daytime Anesthesiology Department, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
Purpose: This randomized, controlled trial aimed to assess the sedative effects of esketamine and sufentanil combined with propofol during EUS.
Patients And Methods: Three hundred and forty patients undergone EUS were randomly divided into two groups to receive esketamine 0.25 mg/kg combined with propofol (esketamine group) or sufentanil 0.
Front Pharmacol
January 2025
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy and School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Objective: The present study aims to explore the initial dosage optimization of sertraline in pediatric major depressive disorder (MDD) patients based on model-informed precision dosing (MIPD).
Methods: A total of 111 pediatric MDD patients treated with sertraline were included for analysis using MIPD. Sertraline concentration levels, physiological and biochemical indexes of pediatric MDD patients, combined drug information were included in the construction of model.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!